MODERN MEDICINE AND PRACTICE
https://inovatus.es/index.php/ejmmp
EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE
Vol. 4 No. 12 (Dec - 2024) EJMMP ISSN: 2795-921X

CLINICAL AND IMMUNOLOGICAL EVALUATION OF THE EFFECTIVENESS OF SURFACTANT THERAPY IN PREMATURE INFANTS WITH VERY LOW BODY WEIGHT

Rustamov Bakhtiyorjon Bobokulovich
Bukhara State Medical Institute, Assistant of the 2nd Department of Pediatrics

Annotation: This article presents the opinions of domestic and foreign scientists on the clinical and immunological evaluation of the effectiveness of surfactant treatment in very low birth weight premature infants. Premature infants with very low birth weight (VLBW, <1500 g) are at high risk for respiratory distress syndrome (RDS) due to insufficient surfactant production. Surfactant therapy has become a cornerstone in the management of RDS, significantly improving survival and reducing complications. Evaluating its clinical and immunological effectiveness is crucial for optimizing outcomes.

Key words: respiratory distress syndrome (RDS), very low birth weight (VLBW), Incidence of Bronchopulmonary Dysplasia (BPD), Oxygen Saturation and Blood Gas Levels, Surfactant proteins (SP-A and SP-D), neonatal intensive care unit (NICU), randomized controlled trial (RCT).

Introduction.

A crucial intervention for the treatment of respiratory distress syndrome (RDS) in preterm newborns, especially those with very low birth weight (VLBW), is surfactant therapy. Through improved gas exchange and a reduction in alveolar surface tension, this treatment seeks to enhance lung function and avoid alveolar collapse. This is a thorough summary of the immunological and clinical assessment of surfactant therapy's efficacy in this population:

Clinical Assessment

1. Results for Newborns:

Surfactant treatment has been found to drastically lower death rates in VLBW babies with RDS, especially those born before 28 weeks of gestation, according to studies.

Requirements for Respiratory Support: Surfactant therapy frequently results in a shorter period of respiratory support and a lower demand for mechanical ventilation, which improves clinical outcomes.

The incidence of bronchopulmonary dysplasia (BPD), a serious long-term consequence of RDS, has been found to be decreased in preterm infants receiving surfactant treatment.

2. Metrics for Clinical Improvement:

- Oxygen Saturation and Blood Gas Levels: Numerous studies show notable changes in arterial blood gas values and oxygen saturations following surfactant treatment, suggesting improved lung function.

Days on Ventilator: Surfactant administration is linked to fewer days spent in need of mechanical ventilation.

3. Administration Timing: The efficacy of surfactant therapy is also correlated with when it is administered, with early postpartum intervention yielding better results than postponed treatment.

Immunological Assessment

1. Modulation of the Immune Response: Surfactant treatment is believed to have immunomodulatory effects. According to research, surfactants may lessen pulmonary damage and encourage recovery by influencing the inflammatory response in the lungs.

2. Cytokine Levels: Research assessing cytokine levels in infants undergoing surfactant therapy has revealed an increase in anti-inflammatory mediators and a decrease in pro-inflammatory cytokines (like TNF-alpha and IL-6), indicating that surfactant therapy may aid in regulating the immune response in the lungs.

3. Effect on Pulmonary Surfactant Proteins: SP-A and SP-D, two surfactant proteins, are essential for the lungs' immunological defence. An understanding of the immunological component of surfactant therapy may be gained by comparing the levels of these proteins before and after treatment.

4. The possibility of infection: The risk of infection has also been examined in relation to surfactant usage. Although caution is still required, some research indicates that surfactant treatment may not substantially raise the risk of infection, even if it may postpone the start of RDS.

For preterm babies with extremely low birth weights, surfactant treatment has proven to be an essential intervention, especially when it comes to treating respiratory distress syndrome (RDS). Several techniques are used in contemporary clinical and immunological evaluations of surfactant therapy's efficacy:

Clinical Assessment

1. Parameters of respiration Monitoring includes measuring arterial blood gases, respiratory rate, and oxygen saturation both before and after surfactant delivery.

Assessment of the infant's post-treatment positive airway pressure requirements and need for mechanical ventilation.

2. Clinical Ratings:

To evaluate clinical progress in respiratory status, grading methods like the Neonatal RDS Severity Score and the Silverman Score are used.

Keep an eye out for indications of better lung function, less respiratory effort, and general clinical stability.

3. Immediate and Prolonged Results:

Monitoring the incidence of bronchopulmonary dysplasia (BPD), days spent on mechanical ventilation, and duration of stay in the newborn intensive care unit (NICU).

Evaluations of the child's neurological and respiratory development over an extended period of time.

Immunological Assessment

1. Biomarker Studies: To evaluate lung inflammation after surfactant treatment, inflammatory markers (such as interleukins and cytokines) are measured in blood or tracheal aspirates.

Monitoring levels of surfactant proteins (SP-A, SP-B) to assess lung function and the efficacy of surfactant replacement.

2. Pulmonary Function Tests: - Performing tests like plethysmography or oscillometry to evaluate lung mechanics after therapy, especially when the infants live to a later age.

Assessing respiratory resistance and compliance, which may be a sign of how well surfactant treatment is working.

3. Immunological Response Assessment: T-cell populations, natural killer (NK) cells, and other immunological markers in the blood are measured in order to analyse the immune response.

Evaluation of general immune function, including the existence of infections or sepsis, which may impede the effectiveness of surfactant therapy.

Imaging Methods

1. Chest X-rays and ultrasounds: routine imaging tests to evaluate the structure and function of the lungs, searching for atelectasis symptoms and improvements in lung expansion following the administration of surfactants.

Lung aeration can also be measured in real time using ultrasound.

2. High-Resolution Computed Tomography (HRCT): In some situations, HRCT scans can be used to study long-term results and chronic lung illness, as well as to provide a complete evaluation of lung architecture and any damage following surfactant therapy.

Investigations and Developments

ongoing research on the unique impact of novel surfactant formulations (such as synthetic and protein-rich surfactants) on the immune response.

research on supplemental treatments (such postnatal corticosteroids) that might improve surfactant therapy's efficacy and have an impact on long-term results.

Assessment of Surfactant Therapy's Clinical and Immunological Effectiveness in Premature Infants with Very Low Body Weight (VLBW)

This describes a possible research design that takes into account both clinical and immunological factors in order to assess the efficacy of surfactant treatment in VLBW preterm newborns.

I. Overview:

Surfactant insufficiency puts premature newborns at increased risk for respiratory distress syndrome (RDS), particularly those with very low birth weights (VLBW, <1500g). A vital component of newborn care, surfactant replacement treatment dramatically increases survival and lowers morbidity. Research is still ongoing to determine the best practices and the long-term immunological implications, though. The purpose of this study is to thoroughly evaluate the immunological and clinical effects of surfactant treatment in VLBW newborns.

II. Research Design:

The most reliable design would be an RCT, or randomised controlled experiment.

Participants: VLBW babies (less than 1500 grammes) who were diagnosed with or at high risk for RDS and admitted to the Neonatal Intensive Care Unit (NICU). Clear definitions of the inclusion and exclusion criteria (such as congenital defects, serious infections, and substantial co-morbidities) will be provided.

Using randomisation Participants will be split into one of two groups at random:

Intervention group: Getting surfactant treatment (name the kind and dose schedule).

Standard care, maybe with supported breathing but without surfactant, is given to the control group. It might not be morally acceptable to conduct a placebo-controlled experiment. An alternative dose schedule or comparison to another surfactant could also be taken into account.

Blinding: Although it might be difficult in this situation to blind physicians and assessors, efforts should be taken to reduce bias by using standardised data collecting methods and, when practical, blinded evaluations (such as radiological interpretation).

The sample size was determined using power analysis and clinically relevant objectives, such as the incidence of bronchopulmonary dysplasia (BPD), length of mechanical ventilation, and mortality reduction.

III. Results in Clinical Practice:

Principal Results:

mortality rate at 28 days and 36 weeks of corrected gestation.

length of time spent on mechanical ventilation.

BPD prevalence and severity at corrected gestational age of 36 weeks.

Extracorporeal membrane oxygenation (ECMO) is required.

Secondary Results:

duration of hospitalisation.

indicators of oxygen saturation.

requires for respiratory assistance, such as nasal continuous positive airway pressure (CPAP) and high-frequency oscillatory ventilation.

prevalence of other respiratory issues, such as pulmonary haemorrhage and pneumothorax.

Growth metrics (head circumference, weight, and length).

neurodevelopmental outcomes (e.g., Bayley Scales of Infant Development) at 18–24 months.

IV. Endpoints of Immunology:

Samples of blood: collected at the beginning of therapy, at different intervals (e.g., 24 hours, 7 days, and just after the administration of a surfactant), and at the end of treatment.

Evaluations:

Markers of inflammation: Analysis of blood and bronchoalveolar lavage (BAL) fluid for cytokines (e.g., IL-6, TNF-α, IL-10), chemokines, and other inflammatory mediators (if possible).

Subsets of immune cells: Flow cytometry is used to analyse leukocyte populations (such as neutrophils, lymphocytes, and macrophages) in peripheral blood and BAL fluid.

Assays for immune function: Evaluation of immune cell activity, such as phagocytosis and cytokine synthesis.

Analyse changes in the makeup of the gut microbiota in relation to immunological development and respiratory consequences.

The clinical and immunological results of the intervention and control groups will be compared statistically using the proper techniques (e.g., t-tests, chi-squared tests, survival analysis). The associations between clinical, immunological, and other variables (such as gestational age, birth weight, and delivery method) will be investigated by multivariate analysis.

Moral Points to Remember:

The appropriate Institutional Review Board (IRB) or Ethics Committee must approve the study, which will be carried out in compliance with the Declaration of Helsinki. Parents or legal guardians will be asked for their informed permission.

Restrictions:

Potential drawbacks of this research design are acknowledged, including the challenge of blinding, the possibility of confounding variables, and the intrinsic heterogeneity in surfactant treatment response.

Conclusion.

For the treatment of respiratory distress syndrome (RDS) in preterm newborns, especially those with very low birth weight (VLBW), surfactant therapy is an essential intervention. Its efficacy has been thoroughly assessed by immunological and clinical research.

Surfactant treatment, which significantly improves clinical outcomes and advantageously modulates the immunological response, is a cornerstone in the care of RDS in VLBW babies. To further improve the timing, dose, and formulation of surfactants and increase their efficacy and safety in this susceptible group, more research and clinical studies are necessary. In neonatology, it is still crucial to continuously assess long-term results and the possible effects of surfactant treatment on immunological and lung health.

When taken as a whole, these contemporary techniques not only offer a thorough assessment of surfactant therapy's efficacy but also enable focused efforts to enhance treatment plans for children with extremely low birth weights. To maximise treatment for this susceptible group, ongoing developments in clinical procedures and immunological knowledge are essential.

List of used literatures:

1. Mead, J., and Avery, M. E. (1959). Surface characteristics in connection with hyaline membrane illness and atelectasis. AMA Children's Diseases Journal, 97(5), 517-523.
2. Ikegami, M., and Jobe, A. H. (1998). mechanisms that cause lung damage in premature infants. 53(1), 81-94; Early Human Development.
3. Richmond, P., Simmer, K., Strunk, T., Currie, A., & Burgner, D. (2011). Human newborns with innate immunity: preterm is more than just immaturity. 24(1), 25–31; Journal of Maternal-Fetal & Neonatal Medicine.
4. Moss, T. J. M., and Melville, J. M. (2013). the effects of premature birth on the immune system. Neuroscience Frontiers, 7, 79.
5. Ballard, R. A., and P. L. Ballard (1995). Prenatal glucocorticoid use: scientific foundation and treatment plans. 173(1), 254-262, American Journal of Obstetrics and Gynaecology.
6. Morley, C. J., and R. F. Soll (2001). Using surfactant prophylactically as opposed to selectively can help reduce morbidity and death in premature babies. Database of Systematic Reviews, Cochrane, 2.
7. Bose, C., Van Marter, L. J., Allred, E. N., O'Shea, T. M., & Laughon, M. (2011). Developmental delay and chronic lung illness at age two in children born before 28 weeks. e726–e732 in Paediatrics, 127(3).
8. Fanaroff, A. A., and Hack, M. (2000). results of infants born in the 1990s with exceptionally low gestational ages and birthweights. 1953(3), Early Human Development, 193-218.